Style | Citing Format |
---|---|
MLA | Afrisham R, et al.. "Anti-Inflammatory Effects of Plasma Circulating Exosomes Obtained From Normal-Weight and Obese Subjects on Hepatocytes." Endocrine# Metabolic and Immune Disorders - Drug Targets, vol. 21, no. 3, 2021, pp. 478-484. |
APA | Afrisham R, Sadeghnejadi S, Meshkani R, Emamgholipour S, Bagherieh M, Paknejad M (2021). Anti-Inflammatory Effects of Plasma Circulating Exosomes Obtained From Normal-Weight and Obese Subjects on Hepatocytes. Endocrine# Metabolic and Immune Disorders - Drug Targets, 21(3), 478-484. |
Chicago | Afrisham R, Sadeghnejadi S, Meshkani R, Emamgholipour S, Bagherieh M, Paknejad M. "Anti-Inflammatory Effects of Plasma Circulating Exosomes Obtained From Normal-Weight and Obese Subjects on Hepatocytes." Endocrine# Metabolic and Immune Disorders - Drug Targets 21, no. 3 (2021): 478-484. |
Harvard | Afrisham R et al. (2021) 'Anti-Inflammatory Effects of Plasma Circulating Exosomes Obtained From Normal-Weight and Obese Subjects on Hepatocytes', Endocrine# Metabolic and Immune Disorders - Drug Targets, 21(3), pp. 478-484. |
Vancouver | Afrisham R, Sadeghnejadi S, Meshkani R, Emamgholipour S, Bagherieh M, Paknejad M. Anti-Inflammatory Effects of Plasma Circulating Exosomes Obtained From Normal-Weight and Obese Subjects on Hepatocytes. Endocrine# Metabolic and Immune Disorders - Drug Targets. 2021;21(3):478-484. |
BibTex | @article{ author = {Afrisham R and Sadeghnejadi S and Meshkani R and Emamgholipour S and Bagherieh M and Paknejad M}, title = {Anti-Inflammatory Effects of Plasma Circulating Exosomes Obtained From Normal-Weight and Obese Subjects on Hepatocytes}, journal = {Endocrine# Metabolic and Immune Disorders - Drug Targets}, volume = {21}, number = {3}, pages = {478-484}, year = {2021} } |
RIS | TY - JOUR AU - Afrisham R AU - Sadeghnejadi S AU - Meshkani R AU - Emamgholipour S AU - Bagherieh M AU - Paknejad M TI - Anti-Inflammatory Effects of Plasma Circulating Exosomes Obtained From Normal-Weight and Obese Subjects on Hepatocytes JO - Endocrine# Metabolic and Immune Disorders - Drug Targets VL - 21 IS - 3 SP - 478 EP - 484 PY - 2021 ER - |